Autologous and allogeneic @entity8 in XXXX : review of the literature and future directions.

@entity1 @entity8 @entity2353 @entity1071 @entity66 @entity2225 @entity8057 @entity204
@entity8057 ( @entity8057 ) is a @entity1071 characterized by lymphoplasmacytic infiltrate and a monoclonal IgM serum peak. Treatment includes cytotoxic chemotherapy with alkylators, or purine @entity2353 analogues and monoclonal anti- @entity2225 antibody. The role of @entity8 ( @entity8 ) in @entity8057 has not been established. We identified 24 published cases of @entity8057 treated with high-dose chemotherapy (HDC) followed by autologous @entity8 (ASCT). The median age was 50 years; half of the @entity1 had refractory disease and received a variety of preparative regimens. Nine complete and 14 partial responses were observed, with one @entity204 . Fifteen @entity1 were alive and well at follow-ups ranging from 1 to 132 months. Six additional @entity1 , with a median age of 45 years (range, 30 to 62), who received allogeneic @entity8 have been reported. All were heavily pretreated with refractory or @entity66 . Median time from diagnosis to transplant was 3.1 years (range, 1.3 to 7). Two @entity1 died of complications of the procedure while one died of disease progression. Three @entity1 were alive and well between 5 and 112 months post-transplant. The small number of reported @entity1 precludes any significant conclusion except that @entity8 is feasible in @entity8057 and long-term disease control can be achieved in selected @entity1 with autologous or allogeneic @entity8 , even in those with refractory disease.
